A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.

NCT Number	NCT07629726
Lead Sponsor	Kyowa Kirin Co., Ltd.
Conditions	Hematologic Neoplasms
Enrollment	72 participants
Start Date	2026-08
Primary Completion	2027-04 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-07